Diabetes News

A cohort of veterans with type 2 diabetes and reduced kidney function prescribed metformin monotherapy were less likely to experience a major adverse cardiovascular event during 4 years of follow-up when compared with similar adults prescribed sulfonylurea therapy, according to findings published in JAMA.

The FDA approved a new indication for the SGLT2 inhibitor canagliflozin to reduce the risk for end-stage renal disease, worsening of kidney function, cardiovascular death and hospitalization for heart failure among adults with type 2 diabetes and diabetic kidney disease, according to a press release from Janssen.

Researchers have identified 16 genetic variants in patients with type 1 diabetes that may increase their likelihood of subsequently developing kidney disease.

None of the more than 1,400 patients with prediabetes were formally referred to the CDC’s National Diabetes Prevention Program, according to findings recently published in the Journal of the American Board of Family Medicine.

Only about one in five patients with diabetic foot diseases in Turkey engaged in what researchers called “good” foot care, according to findings published in Primary Care Diabetes.

A meta-analysis of four recent cardiovascular and kidney outcomes trials assessing the use of SGLT2 inhibitors among patients with type 2 diabetes suggests that the drug class offers nephroprotective benefits across all levels of kidney function, regardless of albuminuria status, according to findings published in The Lancet Diabetes & Endocrinology.

Later age at menopause was associated with lower risk for type 2 diabetes, according to a meta-analysis published in Primary Care Diabetes.

The FDA granted fast track designation for the development of Farxiga for patients with chronic kidney disease, according to a press release from AstraZeneca.

As the structure grows internally for Kidney Disease: Improving Global Outcomes, the nonprofit organization has work in the pipeline that includes new guidelines under development, outdated guidelines under revision and changes in process to make work more efficient and accessible. John Davis, the CEO of Kidney Disease: Improving Global Outcome (KDIGO), shared the new and update guidelines and processes in the works with Nephrology News & Issues.

Mobile cardiac telemetry monitors detected high rates of preclinical cardiac arrythmias in patients with chronic kidney disease and type 2 diabetes, according to a published study. Monitoring these patients for such abnormalities may help prevent clinically significant cardiovascular events, such as sudden cardiac death.